ExonHit and Agilent Collaborate to Distribute SpliceArrays Worldwide
News Sep 02, 2005
ExonHit Therapeutics and Agilent Technologies Inc. have announced that SpliceArrays, microarrays to detect alternative splicing, can be purchased directly from Agilent.
SpliceArrays previously had been available only through ExonHit’s SpliceArray Service, which was announced in February.
Agilent claims that, the SpliceArrays’ design allows the detection of both the reference and alternatively spliced forms of targeted genes on Agilent’s microarray platform.
Customers can purchase SpliceArrays from Agilent through a license agreement with ExonHit for access to ExonHit’s proprietary microarray content.
License fees are directly proportional to the number of SpliceArrays purchased, with significant discounts for volume commitments and no reach-through rights.
“We have a growing list of clients from both the industrial and academic sectors,” said Bruno Tocque, CEO of ExonHit.
“And we are confident that ExonHit’s patented designs for monitoring splicing via microarray will become the industry standard.”
“ExonHit’s SpliceArrays utilize a combination of probes directed at both exons and junctions. This design allows specific detection of both molecular species resulting from each splicing event.”
“Agilent continually seeks opportunities to work with organizations developing useful microarray applications,” said Fran DiNuzzo, vice president and general manager of Agilent’s Life Sciences and Chemical Analysis group’s Integrated Biology Systems.
“This collaboration with ExonHit is a good example of how this approach generates superior value for life science researchers.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.